Publication

Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial)

Carrasco, R., Ramirez, M. C., Nes, K., Schuster, A., Aguayo, R., Morales, M., Ramos, C., Hasson, D., Sotomayor, C. G., Henriquez, P., Cortes, I., Erazo, M., Salas, C. & Gormaz, J. G., 4-Feb-2020, In : TRIALS. 21, 1, 10 p., 137.

Research output: Contribution to journalArticleAcademicpeer-review

  • Rodrigo Carrasco
  • Maria Cristina Ramirez
  • Kjersti Nes
  • Andres Schuster
  • Ruben Aguayo
  • Marcelo Morales
  • Cristobal Ramos
  • Daniel Hasson
  • Camilo G. Sotomayor
  • Pablo Henriquez
  • Ignacio Cortes
  • Marcia Erazo
  • Claudio Salas
  • Juan G. Gormaz

Background: Anthracycline-induced cardiotoxicity (AIC), a condition associated with multiple mechanisms of damage, including oxidative stress, has been associated with poor clinical outcomes. Carvedilol, a β-blocker with unique antioxidant properties, emerged as a strategy to prevent AIC, but recent trials question its effectiveness. Some evidence suggests that the antioxidant, not the β-blocker effect, could prevent related cardiotoxicity. However, carvedilol's antioxidant effects are probably not enough to prevent cardiotoxicity manifestations in certain cases. We hypothesize that breast cancer patients taking carvedilol as well as a non-hypoxic myocardial preconditioning based on docosahexaenoic acid (DHA), an enhancer of cardiac endogenous antioxidant capacity, will develop less subclinical cardiotoxicity manifestations than patients randomized to double placebo. Methods/design: We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast cancer patients undergoing anthracycline treatment. The trial includes four co-primary endpoints: changes in left ventricular ejection fraction (LVEF) determined by cardiac magnetic resonance (CMR); changes in global longitudinal strain (GLS) determined by two-dimensional echocardiography (ECHO); elevation in serum biomarkers (hs-cTnT and NT-ProBNP); and one electrocardiographic variable (QTc interval). Secondary endpoints include other imaging, biomarkers and the occurrence of major adverse cardiac events during follow-up. The enrollment and follow-up for clinical outcomes is ongoing. Discussion: We expect a group of anthracycline-treated breast cancer patients exposed to carvedilol and non-hypoxic myocardial preconditioning with DHA to show less subclinical cardiotoxicity manifestations than a comparable group exposed to placebo. Trial registration: ISRCTN registry, ID: ISRCTN69560410. Registered on 8 June 2016.

Original languageEnglish
Article number137
Number of pages10
JournalTRIALS
Volume21
Issue number1
Publication statusPublished - 4-Feb-2020

    Keywords

  • CarDHA, Chemotherapy-induced cardiotoxicity, Anthracyclines, Carvedilol, DHA, Study protocol, BREAST-CANCER, ANTHRACYCLINE CARDIOTOXICITY, ATRIAL-FIBRILLATION, HEART-FAILURE, FATTY-ACIDS, CHEMOTHERAPY, DYSFUNCTION, DEXRAZOXANE, PROTECTION, THERAPY

Download statistics

No data available

ID: 132974373